Opportunities

The DxR2 program will solicit new point of care/remote-use products with domestic manufacturing capabilities which address test development for Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) biothreats to include glanders, botulism, tularemia, typhus, smallpox, and plague.

BARDA anticipates requesting project proposals for a partner(s) that has the expertise to design, promote, and administer effective prize competitions. With this prize approach, BARDA aims to spur participation from a broad range of organizations, including nontraditional private partners, to develop technical solutions that thrive beyond prize award.

The objective of the prize competitions would be to catalyze innovation in new manufacturing technologies that will improve access and enable faster, lower cost, rapid, and flexible production of medical countermeasures for health security threats.

BARDA anticipates to support at least two prizes through the Prize Administrator selected through this Request for Project Proposals (RPP).  The topics for those prizes are anticipated to be: (1) advance clinical testing of vaccines that leverage new GMP manufacturing approaches for single dose vaccines and (2) innovative approaches to improve the speed, yield, and scale up of non-vector/non nucleic acid-based vaccine manufacturing platforms (i.e., not RNA/DNA or viral-based) to enable rapid sequence-to-release of GMP clinical trial material in line with 100-day mission goals and Phase 1 testing.